SALT LAKE CITY — Faricimab demonstrated “rapid improvements” in anatomic features across previously treated and treatment-naïve patients, according to 3-year study results.
“The TRUCKEE study is a real-world study investigating the efficacy and safety of faricimab in neovascular age-related macular degeneration,” Hannah Khan, MPH, told Healio at the Association for Research in Vision and Ophthalmology meeting. “We are now at 3 years, and we’re seeing maintenance in vision and fluid status.”
Khan and colleagues conducted a retrospective chart